• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300482.SZ
Share

Guangzhou Wondfo Biotech Co.,Ltd Stocks

CN¥ 18.14Last Updated 28.05.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.29B

CN¥ 18.14
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood gas, optical coagulation, and dry chemistry analyzers. The company was founded in 1992 and is headquartered in Guangzhou, China.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300482.SZ is 27 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.05.2026 02:41

Iranian media reported warning strikes on ships attempting to pass Hormuz

29.05.2026 01:39

U.S. stock market hits four records: investors await U.S.-Iran agreement

29.05.2026 00:43

Anthropic has surpassed OpenAI to become the most expensive AI startup. The valuation is close to $1 trillion

29.05.2026 00:08

Anthropic has introduced a new AI model. It can doubt the accuracy of its answers

28.05.2026 23:49

Stocks rebound: investors encouraged by the announcement of the US-Iran deal

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026